Nu Holdings Ltd. (NU) Stock News

Krispy Kreme has been downgraded to a Zacks Rank #5 (Strong Sell) due to multiple structural challenges. The surge in GLP-1 weight-loss drug adoption is significantly reducing demand for sugary baked goods, with studies showing sweet bakery purchases plunge nearly 10% after patients start these medications. Additionally, the company faces negative revenue growth projections through 2027, chronic stock underperformance (down 78.8% over 5 years), a deteriorating balance sheet with debt-to-equity ratios nearly tripling since 2022, and a stock price below $3 that deters institutional investors.

Nucor (NUE) gained 1.7% in recent trading, outperforming the S&P 500's 0.6% gain. The steel company is expected to report earnings of $5.85 per share on October 26, 2026, representing 122.43% year-over-year growth, with projected annual earnings of $18.89 per share (+145.01% YoY). Nucor holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 13.03, trading at a PEG ratio of 0.87.

Nu Holdings (NU) rallied 23.1% in October following Brazil's presidential election and the company's first billion-dollar quarterly profit. With 139 million customers and expanding operations in Mexico and the U.S., NU trades at a reasonable valuation discount to peers. However, rising delinquencies and U.S. expansion costs present risks, warranting a cautious approach for investors.

Grabar Law Office is investigating securities fraud and fiduciary duty breach claims against four companies: Aardvark Therapeutics for allegedly misrepresenting the safety profile of its drug candidate ARD-101 before a clinical hold was placed; Coastal Financial Corporation for failing to disclose deterioration in its CCBX partner loan portfolio and credit losses; Erasca, Inc. for making misleading statements about its ERAS-0015 therapy and improper comparisons to competitors; and New Era Energy & Digital for overstating progress on its data center project and allegedly engaging in fraudulent oil-and-gas schemes.

Nu Holdings Ltd. (NU) shares surged 13% in the last trading session on strong volume, driven by Brazil's election-driven market rally and improved sentiment toward business-friendly policies. The company is expected to report quarterly earnings of $0.23 per share (+35.3% YoY) and revenues of $5.73 billion (+37.3% YoY). However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that the stock may struggle to sustain momentum without further positive estimate revisions. NU currently holds a Zacks Rank #3 (Hold).

Nu Holdings Ltd. (NU) has been trending on Zacks.com despite a -17.8% decline over the past month. The company shows strong fundamentals with expected earnings growth of +35.3% for the current quarter and +38.7% for the fiscal year, along with robust revenue growth forecasts of +42.7% for the current year. However, the stock carries a Zacks Rank #3 (Hold) rating and trades at a premium valuation (Grade D), suggesting it may perform in line with the broader market in the near term.

The Nuveen ESG Large-Cap Growth ETF (NULG) is a smart beta ETF with $3.04 billion in assets, offering exposure to large-cap growth stocks with a focus on ESG criteria. The fund has a low expense ratio of 0.26%, year-to-date returns of 16.35%, and is heavily concentrated in technology stocks (50.7%), with Nvidia as its largest holding at 17.08%. The article also compares it to alternative ESG ETFs like ESGV and ESGU.

New Era Energy & Digital (NUAI) surged 30.6% following announcement of a 20-year power purchase agreement with Vistra for 200-207 MW of power for its Texas Critical Data Center project. However, the company faces headwinds with expected quarterly losses of $0.11 per share (up 45% year-over-year) and declining revenues. With unchanged earnings estimates over the past 30 days and a Zacks Rank #3 (Hold), analysts question whether the recent rally can sustain.

Nu Holdings Ltd. (NU) declined 1.37% on September 18, 2026, underperforming the broader market. Despite the stock weakness, the company shows strong growth prospects with projected EPS up 35.29% and revenue up 37.3% year-over-year. NU holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 16.02, trading at a premium to its industry average.

The article provides an analysis of the Nuveen ESG Mid-Cap Value ETF (NUMV), a smart beta ETF launched in 2016 with $442.53 million in assets. NUMV tracks the TIAA ESG USA Mid-Cap Value Index with a 0.31% expense ratio and has returned 11.92% year-to-date and 14.53% over the past year. The fund holds 89 companies with heaviest exposure to Financials (19.6%), Industrials, and Information Technology sectors. Alternative ESG ETFs like ESGV and ESGU are also mentioned as comparable options.

Nucor stock declined 1.85% on September 14, 2026, underperforming the S&P 500's 0.48% loss. Over the past month, NUE shares fell 3.53% while the Basic Materials sector gained 0.06%. Despite the recent weakness, analysts project strong earnings growth with Q3 EPS expected at $5.58 (up 112% YoY) and full-year earnings of $18.52 per share (up 140% YoY). The stock trades at a Forward P/E of 14.01, below its industry average, and holds a Zacks Rank #3 (Hold) rating.

Nucor stock declined 1.79% on September 8, 2026, underperforming the S&P 500's 0.58% loss and lagging the Basic Materials sector. Despite strong earnings projections showing 107.60% EPS growth and 22.4% revenue growth for the upcoming quarter, the stock has lost 4.93% over the past month. Nucor holds a Zacks Rank #3 (Hold) with a Forward P/E of 14.54, slightly above its industry average.

Zacks highlights the robotics and AI sector as a major growth opportunity, with the general-purpose robotics market projected to grow from under $1 billion in 2025 to $370 billion by 2040. The article examines key industry players including Fanuc, ABB, Keyence, NVIDIA, Intuitive Surgical, and Illumina, and recommends four robotics-focused ETFs (BOTZ, ROBO, ROBT, IBOT) as diversified investment vehicles to capitalize on this trend.

Broad Arrow Auctions, driven by Hagerty, is hosting its second annual Zürich Auction on November 7, 2026, at the Dolder Grand. The sale will feature approximately 60 collector cars, headlined by a rare 2019 McLaren Senna (est. CHF 1.1-1.4M) and a 2015 Ferrari LaFerrari offered without reserve (est. CHF 5.5-7.5M), alongside a 2011 Lamborghini Gallardo LP570-4 Superleggera. The auction continues Broad Arrow's partnership with Auto Zürich.

CLINUVEL Pharmaceuticals announced its tenth consecutive annual profit for FY2026 with revenues of $94.0 million and net profit after tax of $33.9 million. The company declared a $0.05 per share dividend and increased cash reserves to $252.1 million, providing financial independence to pursue expansion strategy, particularly in North America. Despite marginal revenue decline due to U.S. market competition and inventory practice changes, the company maintained disciplined expense control and achieved record SCENESSE treatment volumes.

VINCI, a French public limited company, disclosed its capital structure as of 31 July 2026, with 587,033,654 total shares and €1,467,584,135.00 in share capital. The company announced the implementation of its share buyback programme through a share purchase agreement signed with an investment partner.

Grabar Law Office has initiated multiple shareholder investigations into alleged securities fraud and fiduciary duty breaches at EquipmentShare.com, Insulet Corporation, New Era Energy & Digital, and Planet Fitness. The investigations allege undisclosed related-party transactions, defective manufacturing controls, misleading statements about business progress, and false marketing claims that caused shareholders to purchase securities at artificially inflated prices.

Ferrari N.V. announced Q2 2026 net revenues of €1,938 million (up 8% YoY), operating profit of €605 million with a 31.2% margin, and net profit of €463 million. The company raised its 2026 guidance citing stronger-than-expected personalizations and lower currency headwinds. The order book covers deliveries through 2027, with new model launches including the Ferrari Luce and 12Cilindri Manuale contributing to the company's most complete product lineup in history.

Onco360, the nation's leading independent specialty pharmacy, has been selected as a pharmacy partner by Rigel Pharmaceuticals for VEPPANU (vepdegestrant), an FDA-approved PROTAC estrogen receptor degrader for treating ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. In the Phase 3 VERITAC-2 trial, vepdegestrant demonstrated a 43% reduction in disease progression or death risk compared to fulvestrant in patients with ESR1 mutations.

Grabar Law Office announced investigations into multiple publicly traded companies on behalf of shareholders, alleging breaches of fiduciary duties and securities law violations. The investigations cover Erasca (misleading statements about ERAS-0015 drug candidate and patent infringement), Insulet (defective manufacturing controls leading to product recalls), New Era Energy & Digital (overstated project progress and fraudulent oil-and-gas schemes), Power Solutions International (overstated sales demand and understated manufacturing costs), Hub Group, Planet Fitness, Primoris Services, EquipmentShare.com, GPGI, Photronics, and Via Transportation. Shareholders who meet specific holding criteria may seek damages and corporate governance reforms at no cost.

CLINUVEL Pharmaceuticals announced a strategic reorganisation effective January 1, 2027, relocating its corporate headquarters from Australia to the United States and reducing its global workforce by 10-20%. The restructuring aims to strengthen U.S. regulatory engagement, focus operations on the U.S. pharmaceutical market, and unlock deeper capital pools from U.S. investors who prefer U.S.-listed companies. The move is driven by the company's recognition that U.S.-listed specialty pharma companies command higher valuation multiples and that over 66% of its shareholder base is already foreign investors.

ARCpoint Inc. (TSXV: ARC), a healthcare technology company, announced it will miss its July 29, 2026 filing deadline for annual financial statements due to lack of available funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and expects to file by September 29, 2026. During the MCTO period, insiders will be restricted from trading shares, though public trading will continue.

Alamar Biosciences announced that its NULISA platform will be featured in over 140 posters and presentations at the Alzheimer's Association International Conference (AAIC) in London. The company highlighted advances in blood-based biomarker profiling, particularly the eMTBR-Tau and BD-pTau217 tests, which can be measured simultaneously with 220+ CNS-related proteins in a single workflow. This represents a four-fold increase from the previous AAIC conference, demonstrating growing adoption of the technology in Alzheimer's research.

Alamar Biosciences announced that its NULISA platform will be featured in over 140 posters and presentations at the Alzheimer's Association International Conference (AAIC) 2026 in London. The company introduced its first multiplex blood immunoassay for eMTBR-Tau, a key Alzheimer's biomarker, which can be detected alongside over 220 disease-related proteins in a single workflow. The data demonstrates that combined detection of BD-pTau217 and eMTBR-Tau improves disease stratification compared to single biomarker testing.

Investor rights law firm Halper Sadeh LLC is investigating four major corporate transactions to determine if shareholders are receiving fair deals. The investigations cover LCI Industries' sale to Patrick Industries, Nuvalent's acquisition by GSK, Dana Incorporated's merger with Eaton Corporation, and Taylor Morrison's sale to Berkshire Hathaway. The firm is examining potential securities law violations and breaches of fiduciary duties, particularly regarding insider benefits and terms that may limit competing offers.

LA21-CDC received grant support from Truist Foundation to expand its Small Business Sustainability Initiative, which provides Philadelphia entrepreneurs with coaching, business systems training, capital readiness support, and AI-powered business tools to strengthen operations and build long-term sustainability.

Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Arcosa (CRH acquisition for $150/share), Fathom Holdings (Bed Bath & Beyond acquisition), Nuvalent (GSK acquisition for $124/share), and Dana Incorporated (Eaton Corporation acquisition).

InnSuites Hospitality Trust (IHT) reported Fiscal Q1 2027 net income of $74,702, a $35,672 improvement year-over-year, with record hotel revenue of $2.2 million and combined occupancy reaching 85.37%. The company continues exploring diversification opportunities including a potential reverse merger, IBC Hotels independent hotel services, and investments in UniGen Power's clean energy technology.

Monteverde & Associates PC is investigating four merger and acquisition transactions on behalf of shareholders. Pacific Financial Corporation is merging with Banner Corporation (0.2633 shares per share), Nuvalent Inc. is being acquired by GSK plc ($124.00 per share), Cross Country Healthcare is being sold to KL Criss Cross Intermediate LLC ($13.25 per share), and Bio Green Med Solution is merging with Future NRG Sdn. Bhd. Shareholders are encouraged to contact the firm regarding potential concerns with these transactions.

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.